A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% ...

New real-world data suggests that seniors who get the RSV vaccine have an 80% lower odds for severe illness. It's yet another ...

A multi-state study, published in The Lancet, is one of the first real world data analyses of the effectiveness of the ...

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

This is the second year pregnant women can get the RSV vaccine. One OB/GYN with AdventHealth Medical Group is not only ...

A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or ...

There were no safety concerns identified among older adults following revaccination with the investigational respiratory syncytial virus vaccine mRNA-1345, and immune responses elicited by ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

The respiratory syncytial virus (RSV) vaccines were about 80% effective in older adults during the 2023-24 respiratory disease season, which was the first season after the shot was approved in the US, ...

The RSV vaccine Abrysvo was highly effective against hospital and ED encounters in a large cohort of older adults with comorbidities and immunocompromising conditions.

The CDC recommends that all individuals aged 75 and older, as well as adults aged 60 and older who are at risk for severe RSV ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...